Evidence of quality of life for hospitalised patients with COVID-19: a scoping review.
No Thumbnail Available
All Authors
Webb, EJ.
King, N.
Howdon, D.
Carrol, ED.
Euden, J.
Howard, P.
Pallmann, P.
Llewelyn, MJ.
Thomas-Jones, E.
Shinkins, B.
LTHT Author
Howard, Philip
Sandoe, Jonathan
Sandoe, Jonathan
LTHT Department
Medicines Management & Pharmacy Services
Pathology
Microbiology
Pathology
Microbiology
Non Medic
Consultant Pharmacist
Publication Date
2024
Item Type
Journal Article
Language
Subject
Subject Headings
Abstract
Background: Information on the quality of life of people hospitalised with COVID-19 is important, both in assessing the burden of disease and the cost-effectiveness of treatments. However, there were potential barriers to collecting such evidence.
Objective: To review the existing evidence on quality of life for people hospitalised with COVID-19, with a focus on the amount of evidence available and methods used.
Design: A scoping review with systematic searches.
Results: A total of 35 papers were selected for data extraction. The most common study type was economic evaluation (N = 13), followed by cross-sectional (N = 10). All economic evaluations used published utility values for other conditions to represent COVID-19 inpatients' quality of life. The most popular quality-of-life survey measure was the Pittsburgh Sleep Quality Index (N = 8). There were 12 studies that used a mental health-related survey and 12 that used a sleep-related survey. Five studies used EQ-5D, but only one collected responses from people in the acute phase of COVID-19. Studies reported a negative impact on quality of life for people hospitalised with COVID-19, although many studies did not include a formal comparison group.
Limitations: Although it used systematic searches, this was not a full systematic review.
Conclusion: Quality-of-life data were collected from people hospitalised with COVID-19 from relatively early in the pandemic. However, there was a lack of consensus as to what survey measures to use, and few studies used generic health measures. Economic evaluations for COVID-19 treatments did not use utilities collected from people with COVID-19. In future health crises, researchers should be vigilant for opportunities to collect quality-of-life data from hospitalised patients but should try to co-ordinate as well as ensuring generic health measures are used more.
Funding: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR132254.
Journal
Health Technology Assessment (Winchester, England)